ATE367815T1 - Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension - Google Patents

Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension

Info

Publication number
ATE367815T1
ATE367815T1 AT01123007T AT01123007T ATE367815T1 AT E367815 T1 ATE367815 T1 AT E367815T1 AT 01123007 T AT01123007 T AT 01123007T AT 01123007 T AT01123007 T AT 01123007T AT E367815 T1 ATE367815 T1 AT E367815T1
Authority
AT
Austria
Prior art keywords
conivaptan
medication
pulmonary hypertension
produce
treatment
Prior art date
Application number
AT01123007T
Other languages
English (en)
Inventor
Maha Ghazzi
Milton Lethan Pressler
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE367815T1 publication Critical patent/ATE367815T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01123007T 2000-10-04 2001-09-26 Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension ATE367815T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23753800P 2000-10-04 2000-10-04

Publications (1)

Publication Number Publication Date
ATE367815T1 true ATE367815T1 (de) 2007-08-15

Family

ID=22894157

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01123007T ATE367815T1 (de) 2000-10-04 2001-09-26 Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension

Country Status (13)

Country Link
US (1) US6740648B2 (de)
EP (1) EP1195166B1 (de)
JP (1) JP3838065B2 (de)
KR (1) KR100445946B1 (de)
AT (1) ATE367815T1 (de)
CA (1) CA2357833C (de)
DE (1) DE60129518T2 (de)
ES (1) ES2288899T3 (de)
HU (1) HUP0104085A3 (de)
IL (1) IL145684A (de)
MY (1) MY136383A (de)
NZ (1) NZ514542A (de)
ZA (1) ZA200108130B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
US20050159985A1 (en) * 2003-11-21 2005-07-21 Bertram Carl T. System and method of stratifying intervention groups and comparison groups based on disease severity index scores and ranges
US10042980B2 (en) 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US8532938B2 (en) 2005-11-17 2013-09-10 The Invention Science Fund I, Llc Testing-dependent administration of a nutraceutical
US20070112796A1 (en) 2005-11-17 2007-05-17 Jung Edward K Research in providing assistance related to health
US20070112592A1 (en) 2005-11-17 2007-05-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Payments in providing assistance related to health
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US8000981B2 (en) * 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US20080103746A1 (en) 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
WO2007087575A2 (en) * 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
ES2601856T3 (es) 2007-06-08 2017-02-16 Mannkind Corporation Inhibidores de la IRE-1A
AU2009257174A1 (en) * 2008-06-09 2009-12-17 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers
US20130288370A1 (en) 2010-10-15 2013-10-31 Cytopherx, Inc. Cytopheresis cartridges and use thereof
AU2012364760B2 (en) 2012-01-09 2018-05-31 Seastar Medical Inc. Cartridge and method for increasing myocardial function
WO2014062888A1 (en) * 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
WO2015171989A1 (en) * 2014-05-08 2015-11-12 University Of Maryland, Baltimore Methods for assessing differential risk for developing heart failure
WO2015193889A1 (en) * 2014-06-18 2015-12-23 Sonivie Ltd. Method for treating secondary pulmonary hypertension
CN110237077A (zh) * 2019-05-10 2019-09-17 辽宁大学 考尼伐坦在制备降血脂药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225402A (en) 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5338755A (en) 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
GB9307527D0 (en) * 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
PL177738B1 (pl) * 1993-07-21 2000-01-31 Yamanouchi Pharma Co Ltd Pochodna benzazepiny skondensowanej z 5-członowym pierścieniem aromatycznym zawierającym azot oraz kompozycja farmaceutyczna zawierająca taką pochodną
NZ271454A (en) 1993-08-26 1997-07-27 Yamanouchi Pharma Co Ltd Difluoro substituted benzazepine derivatives and pharmaceutical compositions
JP2649610B2 (ja) 1993-11-10 1997-09-03 日本たばこ産業株式会社 クロマン誘導体及びその医薬用途
FR2757157B1 (fr) * 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
KR20010034461A (ko) * 1998-01-28 2001-04-25 요시다 쇼지 시기능 장해의 예방 또는 치료제
HU229074B1 (en) * 1999-01-19 2013-07-29 Ortho Mcneil Pharm Inc Tricyclic benzodiazepines as vasopressin receptor antagonists
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck

Also Published As

Publication number Publication date
HU0104085D0 (en) 2001-12-28
NZ514542A (en) 2002-10-25
JP3838065B2 (ja) 2006-10-25
MY136383A (en) 2008-09-30
HUP0104085A2 (hu) 2002-07-29
DE60129518T2 (de) 2008-03-20
CA2357833A1 (en) 2002-04-04
EP1195166A2 (de) 2002-04-10
DE60129518D1 (de) 2007-09-06
HUP0104085A3 (en) 2004-11-29
ZA200108130B (en) 2002-06-06
US6740648B2 (en) 2004-05-25
EP1195166B1 (de) 2007-07-25
IL145684A (en) 2007-06-17
KR20020027237A (ko) 2002-04-13
EP1195166A3 (de) 2003-12-03
US20020128259A1 (en) 2002-09-12
ES2288899T3 (es) 2008-02-01
JP2002128696A (ja) 2002-05-09
CA2357833C (en) 2005-11-15
IL145684A0 (en) 2002-06-30
KR100445946B1 (ko) 2004-08-25

Similar Documents

Publication Publication Date Title
ATE367815T1 (de) Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
ATE457989T1 (de) Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
CY1106439T1 (el) Φυτικα εκχυλισματα και η χρηση τους
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE302017T1 (de) Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden
DE502004006619D1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE445617T1 (de) Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
ATE393775T1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
ATE430160T1 (de) Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
ATE432930T1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
DE60008830D1 (de) Verfahren zur Herstellung von keramischen Zusammensetzungen
DE60228724D1 (de) Verfahren zur herstellung von beraprost und dessen salzen
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
DE60220512D1 (de) Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit
ATE491463T1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
ATE400563T1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE454383T1 (de) Neue verbindungen, deren verwendung und herstellung
ATE469882T1 (de) Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties